Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-3/TICO LY-CoV555 , 2020 NCT04501978

bamlanivimab monotherapy (n=163) vs. placebo (n=151)

randomized controlled trial   low risk of bias

Studied treatment

LY-CoV555
LY-CoV555 at a dose of 7000 mg as a single intravenous infusion over a 1-hour period

Control treatment

placebo

supportive care as background therapy, including the antiviral drug remdesivir and,when indicated, supplemental oxygen and glucocorticoids

Patients

COVID 19 hospitalized

Method

double-blind

31 sites in US, Denmark, Singapore

Remark

Study stopped for futility (seven-category ordinal scale on day 5). As of April 2021, regulatory authorities recommend that bamlanivumab no longer be used because of the potential risk of treatment failure due to the circulation of resistant variants of SARS-CoV-2.